

Targeted Drug Development for Breast Cancer Using Innovative Active Pharmaceutical Ingredients (APIs)

ABSTRACT

Aim: This study reviews the recent trends in targeted drug development against breast cancer using innovative active pharmaceutical ingredients (APIs) to achieve better therapeutic outcomes.

Study Design: A review of literature from 2019 to 2024, exploring active pharmaceutical ingredients being used in breast cancer treatment, focusing on nanotechnology, molecular targeting, and personalized medicine approaches.

Methodology: Extensive review of the literature on peer-reviewed articles was done from Google Scholar, PubMed, Scopus, and Cochrane Library. Inclusion criteria included studies discussing innovative active pharmaceutical ingredients, subtypes of breast cancer, and targeted therapy clinical applications.

Results: A total of 12 key studies were identified from the review that emphasized the transformative potential of APIs in the treatment of breast cancer. Innovation in APIs includes antibody-drug conjugates, polymer-based systems, and nanoparticle-mediated delivery mechanisms have been highlighted to improve drug targeting and minimize systemic toxicity. Moreover, personalized medicine approaches showed a considerable enhancement in therapeutic efficacy.

Conclusion: Innovative APIs are one of the most promising frontiers in the treatment of breast cancer, which overcomes the drawbacks of traditional treatments. However, further research is needed to standardize such developments and make them accessible globally. The findings indicate that advanced technologies must be combined with regulatory frameworks to achieve sustainable advancement in oncology therapeutics.

Keywords: Active Pharmaceutical Ingredient (API), Nanotechnology, Molecular Targeting, Antibody-Drug Conjugates (ADCs)

1. INTRODUCTION

Breast cancer continues to pose a significant global health challenge, ranking as the most diagnosed cancer in women and a leading cause of cancer-related mortality. According to the World Health Organization (WHO), there were 2.3 million new cases of breast cancer diagnosed worldwide, alone in 2020 which accounts for almost 11.7% of all global cancers [1]. Breast cancer is among the leading causes of deaths from cancer in the world today, affecting millions of women globally. It is estimated that approximately 2.3 million new cases of this disease are diagnosed globally each year, with over 600,000 deaths, making it one of the most prevalent and deadly forms of cancer [2]. Although there has been great progress in diagnosis and treatments of breast cancer during the past decades, traditional therapeutic approaches, like chemotherapy, radiation, and hormone therapy, are generally suboptimal for many due to broad-spectrum effects as they kill not only cancerous tissues but healthy ones as well, showing high toxicity and limited efficiency, mostly in advanced stages [3]. Furthermore, the heterogeneity of breast cancer, with its diverse subtypes based on molecular and genetic factors, complicates the search for treatment strategies that can be

applied across the board. These challenges indicate that new approaches to the treatment of cancer need to be more targeted, effective, and less toxic.

The challenge for oncology has, however, seen enormous progress of targeted therapies, which include treatments that directly attack cancer cells while sparing normal tissues. Probably among the most promising developments are innovative active pharmaceutical ingredients based on the advances in nanotechnology, molecular targeting, and personalized medicine. These APIs are targeted at enhancing the specificity of drugs, thereby improving their therapeutic efficacy while minimizing adverse side effects. With the ability to target specific molecular markers on breast cancer cells, these advanced APIs promise to revolutionize treatment paradigms and offer new hope for patients who do not respond well to traditional therapies. Targeted drug development is based on the understanding of molecular and genetic alterations in cancer. Breast cancer is a highly heterogeneous disease and is classified into several subtypes based on genetic expression and receptor status. These include HER2-positive, hormone receptor-positive (HR-positive), and triple-negative breast cancer (TNBC), each of which requires different treatment approaches. For example, HR-positive breast cancers are often treated with hormonal therapies, while HER2-positive cancers can be treated using HER2 inhibitors such as trastuzumab (Herceptin) [4, 5]. However, treatment options for TNBC remain limited because this subtype does not express estrogen, progesterone, or HER2 receptors; thus, conventional therapies often prove ineffective. As mentioned by Schmid et al. [6], this calls for an urgent need for drugs that can target the unique molecular characteristics of each breast cancer subtype, at least for those patients with a worse prognosis.

Innovative APIs will meet this challenge by introducing the latest technologies like nanotechnology, biologics, and immunotherapy. Nanotechnology allows the design of a drug delivery system capable of bringing the therapeutic agent directly into the cancerous cells while significantly reducing off-target effects and systemic toxicity. Such nanocarriers are being developed using liposomes, micelles, and dendrimers to improve the bioavailability and precision of breast cancer drugs [7]. Monoclonal antibodies and targeted small molecule inhibitors are also in development to block specific pathways of cancerous cells, thus disturbing their growth and survival [8]. Immunotherapies, including checkpoint inhibitors, seek to utilize the body's immune system to target and destroy cancerous cells. These treatments have shown promise, especially in circumstances where traditional therapies have failed [9].

Another groundbreaking feature of targeted drug development involves the integration of personalized medicine. Personalized medicine seeks to provide treatment based on unique genetic and molecular profiles in each individual patient. Advances in next-generation sequencing and biomarker discovery enable clinicians to identify mutations, gene amplifications, and specific molecular signatures present in breast cancer cells. By understanding these unique features, clinicians can select therapies that are more likely to be effective for the individual patient, thus enhancing therapeutic outcomes and reducing unnecessary side effects [8]. Personalized approaches also enable the development of companion diagnostics, which are tests used to predict a patient's response to a specific drug, further improving treatment precision and safety.

While the new innovative APIs in the treatment of breast cancer have immense promise, several challenges lie ahead that need to be considered. The first and most crucial is the regulatory approval as newly formulated drugs and delivery systems require rigorous testing for safety and efficacy before approval. The second problem pertains to the manufacture of these advanced APIs, particularly when scaling up production to meet global demand. Furthermore, costs related to the development and production of these therapies are

considered high because they often involve highly specialized facilities and sophisticated technologies. The access to such treatments may be limited, particularly in low- and middle-income countries where cancer care infrastructure might not be that good [10]. Moreover, the long-term side effects of these novel therapies must be extensively studied. While promising, early clinical trials have given way to the need for further research on the durability of responses, possible resistance mechanisms, and long-term safety profiles. Combination therapies that incorporate innovative APIs in addition to existing treatment modalities could further improve the effectiveness of treatments for breast cancer. For example, targeted therapies combined with chemotherapy or immunotherapy exhibit synergistic effects that lead to better clinical outcomes [11, 12].

This review serves to critically analyze the current landscape of targeted drug development through innovative APIs for the treatment of breast cancer. This review will discuss recent advances in systems for drug delivery, molecular targeting, and personalized medicine approaches, focusing on how such novel therapies are setting the future in breast cancer treatment. Additionally, it deliberates on the challenges and future directions in the field, drawing on the need for continued research investment, regulatory development, and global access to these life-saving therapies.

2. METHODOLOGY

The methodology for this review on Targeted Drug Development for Breast Cancer Using Innovative Active Pharmaceutical Ingredients (APIs) follows a systematic and rigorous approach to gather and synthesize the most relevant high-quality research. This review is intended to explore the potential of novel APIs and drug delivery technologies in the advancement of treatments for breast cancer, focusing on emerging therapeutic strategies such as molecular targeting, nanotechnology, and personalized medicine.

Literature Search Strategy

The literature search was conducted in four established electronic databases: Google Scholar, PubMed, Scopus, and Cochrane Library. These databases were chosen to ensure that the biomedical and pharmaceutical literature reviewed is both extensive and reputable. Google Scholar provides access to a wide array of research articles, including clinical trials, preclinical studies, and meta-analyses. PubMed is a trusted source for peer-reviewed studies in the life sciences and medicine, particularly cancer research. Scopus was included because of its wide international coverage and for indexing high-quality journal articles related to pharmaceuticals and oncology. Lastly, Cochrane Library offers comprehensive systematic reviews and evidence-based studies that assess medical interventions and therapies, making it an essential tool for evaluating the effectiveness of novel APIs in cancer treatments.

The search strategy used a combination of targeted keywords and Boolean operators to narrow down the search results. The keywords used to search included "Targeted drug delivery in breast cancer," "Innovative active pharmaceutical ingredients in breast cancer treatment," "Nanotechnology in breast cancer therapies," "Molecular targeting APIs breast cancer," "Personalized medicine in breast cancer," and "Breast cancer drug delivery systems." The keywords were selected with caution to represent a wide variety of therapeutic innovations in the treatment of breast cancer, including molecularly targeted APIs, nanocarriers, and personalized treatment strategies. Boolean operators such as AND, OR, and NOT helped refine the search to ensure that relevant studies were found. The search was limited to articles published between 2019 and 2024 to capture the most current developments in the field. This time frame was chosen to reflect recent developments in

pharmaceutical technologies, especially those dealing with targeted therapies and the use of APIs in oncology. Only studies published in English were included to maintain consistency in data interpretation and analysis.

Selection Process for Studies

The selection process had various steps, starting with title and abstract screening. The studies not meeting the focus on breast cancer, targeted therapies, or innovative APIs were excluded at this initial screening stage. Furthermore, studies focused on conventional chemotherapy or those that did not discuss new drug delivery systems were also eliminated. The next step involved getting the full texts of the remaining articles and reviewing them. Each full-text article was carefully evaluated against the inclusion criteria: peer-reviewed, relevant to targeted drug delivery or APIs in breast cancer, and either clinical, preclinical, or systematic reviews. Articles that did not meet these criteria were excluded. Furthermore, articles published in a language other than English were excluded to avoid any possible translation errors and misinterpretation.

A total of 238 articles were identified through database searches. After removing duplicates, 170 unique articles were found. The titles and abstracts of the articles were screened for studies related to the treatment of breast cancer, APIs, drug delivery systems, and molecular targeting. Articles that did not focus on breast cancer or that did not explore new APIs or drug delivery technologies were excluded. At this stage, 130 articles were excluded. Full-text assessment of eligibility was performed for the remaining 40 articles. The studies were checked for relevance to the research question and methodological rigor. It includes only those articles that present data on innovative APIs, targeted drug delivery systems, or personalized therapies for breast cancer. Thus, studies focusing on traditional chemotherapy, lacking empirical data, or published in languages other than English were excluded. A total of 12 studies were included after the full-text review for qualitative analysis. These studies provided substantial evidence regarding efficacy, safety, and the potential of innovative APIs to improve breast cancer treatment.




Figure 1: Flow diagram of the literature search and study selection for the review.

However, data extraction was done after the full-text assessment; the key data extracted included the type of API or drug delivery system under investigation, the subtype of breast cancer being targeted, the study design, and the primary outcomes of drug efficacy, safety, and patient outcomes. This systematic approach ensures comprehensive coverage and high-quality data synthesis; there are, however, several limitations that need to be recognized. One limitation of the search strategy is that it focused solely on studies published in English. This exclusion of non-English studies may have led to the omission of potentially relevant research from non-English speaking regions, particularly from countries where breast cancer treatment approaches may differ [13]. Moreover, the decision to restrict the review to studies published between 2019 and 2024 may have excluded older, foundational research that could provide valuable context or insights into the evolution of targeted therapies.

Indeed, the quality assessment of the included studies was based on available information and may not always reflect the full methodological rigor of the studies. Sometimes, the relevant data on drug efficacy or safety were either unavailable or incomplete to make definitive conclusions about the effectiveness of a particular API. Besides, the review focused on clinical trials and preclinical studies, while there may be additional useful insights from observational studies, patient surveys, or real-world data that were not captured. Also, the scope of this review focused on APIs and targeted drug delivery systems for breast cancer, and it did not include other forms of cancer treatment, such as immunotherapy or radiation. This narrowing of focus means that the findings of this review may not be fully applicable to other cancer types or therapeutic approaches [14]. Despite these limitations, the methodology applied in this review provides a sound and systematic approach to reviewing the latest developments in targeted drug delivery for breast cancer. The process ensures that the review is informed by high-quality, relevant research and provides a comprehensive understanding of the current state of innovative APIs in the treatment of breast cancer. The results of this review will contribute significant insights into the development of precision oncology therapies, which will pave the way for future research and clinical applications in the field.

3. RESULTS AND DISCUSSION

The comprehensive literature review identified twelve (12) pivotal studies that demonstrate the transformative potential of innovative APIs in breast cancer therapy. These were then categorized according to the type of API innovation they presented, including Anti-body Drug Conjugates (ADCs), polymer-based systems, nanoparticle-mediated delivery mechanisms, and personalized medicine approaches.

Antibody-Drug Conjugates (ADCs)

Several studies have highlighted the effectiveness of ADCs for treating breast cancer through specific tumor antigens. For example, García-Alonso et al. [15], found that trastuzumab emtansine (T-DM1), an ADC targeting HER2-positive breast cancer, showed a marked improvement in progression-free survival for metastatic patients compared to conventional chemotherapy. Similarly, Ferraro et al. [16] reported that novel ADCs targeting HER3 receptors showed enhanced specificity and reduced off-target toxicity in preclinical models of HER2-negative breast cancer. These findings support the concept of ADCs as a highly effective class of therapeutics for both HER2-positive and HER2-negative subtypes of breast cancer.

ADCs combine the specificity of monoclonal antibodies with the potent cytotoxicity of chemotherapy drugs, enabling targeted drug delivery directly to cancer cells. The mechanism of action of ADCs includes several key steps: The antibody component of the ADC binds to a specific receptor, such as HER2 or HER3, overexpressed on the surface of cancer cells [15]. This binding facilitates the internalization of the ADC into the cancer cell via receptor-mediated endocytosis [16]. Once inside the cell, the cytotoxic drug is released by enzymatic cleavage of the linker between the antibody and the drug [17]. The cytotoxic agent then exerts its effects by inducing cell death through mechanisms such as DNA damage or inhibition of mitosis [18]. This precise targeting of cancer cells reduces the exposure of healthy tissues to the drug, minimizing systemic toxicity and enhancing therapeutic efficacy.

Despite their promising potential, challenges remain in optimizing linker technologies, improving the stability of the drug-antibody conjugate, and identifying new antibody targets. In addition, the development of resistance mechanisms can hamper the efficacy of ADCs,

and thus further research is needed [19]. Hence, two important areas for future investigation include the extension of ADCs to more breast cancer subtypes and addressing the issue of resistance development.




Figure 2: Representative mechanistic pathway of ADC in cancer cells.

Polymer-Based Drug Delivery Systems

Polymer-based drug delivery systems have been widely developed for improving the efficacy of drugs and reducing their side effects. Fatima et al. [20] and Lee et al. [21] highlighted a biodegradable polymer matrix capable of controlled release of doxorubicin, resulting in sustained drug exposure and enhanced cytotoxicity against TNBC cell lines. Furthermore, Luo et al. [22] investigated the use of polymeric micelles for the co-delivery of paclitaxel and siRNA, achieving synergistic tumor growth inhibition in vivo. The mechanism of action of polymer-based drug delivery systems involves the use of polymers to encapsulate therapeutic agents in a stable, controlled-release form. Once administered, the polymeric carriers undergo degradation or respond to environmental stimuli such as pH, temperature, or enzymes, triggering the release of the encapsulated drug at the target site [21]. In the case of polymeric micelles, the hydrophilic shell and hydrophobic core allow for the encapsulation of both hydrophobic drugs like paclitaxel and nucleic acids such as siRNA, facilitating their efficient co-delivery [22, 23]. These systems also enable the targeting of specific tumor cells via ligand-receptor interactions, ensuring that therapeutic agents are delivered directly to cancer cells while minimizing exposure to healthy tissues. These polymeric systems offer several advantages, including controlled and sustained drug release, which can prolong therapeutic effects while minimizing side effects. In addition, they enable the delivery of multiple agents simultaneously, facilitating combination therapies [24]. Future studies should be performed to develop biodegradable and stimuli-responsive materials capable of responding to specific environmental triggers, such as the acidic tumor microenvironment, through the release of drugs. Such enhancement in versatility and responsiveness will contribute significantly to clinical translation.




Figure 3: Mechanism of polymeric micelle-based drug delivery for co-delivery of doxorubicin and siRNA in cancer therapy.

Nanoparticle-Mediated Delivery Mechanisms

Nanotechnology has emerged as a power tool in developing targeted therapies against breast cancer. Several studies demonstrated the role of nanoparticles in enhancing drug delivery. For example, Mukherjee and Bandyopadhyay [18], highlighted that gold nanoparticles conjugated with folic acid for targeting the overexpression of folate receptor in certain breast cancer cells, demonstrating improved cellular uptake and induction of apoptosis. Shaikh et al. [25] employed liposomal nanoparticles encapsulating HER2 inhibitors, improving drug solubility and targeted delivery, thereby reducing systemic toxicity. Ponziani et al. [17] explored dendrimer-based carriers for the targeted delivery of microRNA therapeutics, which significantly downregulated oncogenic pathways in breast cancer models.

Nanoparticles offer unparalleled precision in drug delivery, enabling selective accumulation in tumor tissues through functionalization with targeting ligands [26]. Moreover, they can also breach biological barriers, such as the blood-brain barrier, thereby extending the scope of treatments against breast cancer [27]. However, challenges such as nanoparticle stability, immunogenicity, and large-scale manufacturing need to be overcome to realize their full clinical potential. Advances in the design of nanoparticles, including non-immunogenic coatings and functionalization for real-time tracking, may improve their clinical utility.




Figure 4: (a) Distinctive features of various nanoparticles used as drug delivery carriers, and (b) Key advantages of nanoparticle-based drug delivery systems in overcoming chemoresistance [27].

Personalized Medicine Approaches

Personalized medicine is changing the face of breast cancer treatment with therapy selection based on an individual patient profile. Vashisht et al. [28] discussed the potential of next-generation sequencing in identifying actionable mutations among breast cancer patients that could facilitate the selection of targeted therapies. Wolf et al. [19] established companion diagnostics to pre-exercise predictions of patient responsiveness regarding specific active pharmaceutical ingredients, thus enhancing precision within treatment. Furthermore, Thompson et al. [29] reported biomarker profiles and machine learning algorithms as powerful tools to predict overall therapeutic outcomes. This technique also offers an accurate approach to therapy selection across diverse subtypes in human breast cancers. Thus, the integration of genomics, transcriptomics, and proteomics provides the opportunity to identify highly specialized molecular drivers of progression toward personalized treatments. The application of companion diagnostics also complements personalized medicine approaches, bringing real-time insight into the responsiveness of treatments while keeping adverse effects at minimal levels. However, high implementation costs of personalized medicine and a lack of effective data-sharing frameworks continue to challenge full implementation. This will be further refined by the incorporation of multi-omics

data and real-time monitoring of patient responses, thus further improving the outcomes of personalized therapy strategies.

Overall Efficacy and Safety of Innovative APIs

Across the studies reviewed, innovative APIs were more effective and safer than conventional treatments for breast cancer. Enhanced targeting allowed higher drug concentrations at the tumor site with minimal systemic exposure, leading to fewer side effects. Clinical trials reported favorable response rates, extended survival times, and manageable adverse effects, especially in HER2-positive and TNBC populations. These findings give reason to believe that such advanced therapies have the potential to provide better clinical outcomes for breast cancer patients. Despite such promising results, there are still many challenges ahead. Regulatory barriers, the complexity of new drug formulations, and high development costs are significant obstacles to the wide use of such therapies. Moreover, consistency in manufacturing and quality control is also crucial for the successful translation of innovative APIs from the laboratory into the clinic. These challenges, however, will be resolved through collaborative effort from academia, industry, and regulatory bodies themselves to ensure equitable distribution of cutting-edge therapies.

Challenges and Future Directions

While the reviewed studies reveal the considerable potential of innovative APIs in breast cancer management, challenges must be addressed to make these therapies clinically viable. Most notably, there are several regulatory challenges related to approval and registration of new drug formulations. The new modalities are very complex, requiring proper safety and efficacy testing. Standardization of manufacturing and scalability are very critical for large-scale application. Furthermore, the high development and production cost remains a big challenge for access in resource-poor settings. Such hurdles can be best addressed with a collaboration of effort by academia, industry, and regulatory sectors that could provide equitable access to new therapies. Further, long-term follow-up will be required to fully understand the durability of therapeutic responses, development of resistance mechanisms, and optimal therapy combinations. The combination of innovative APIs with existing treatment modalities such as immunotherapy or hormonal therapy may offer synergistic benefits and prevent resistance development.

4. CONCLUSION

Innovative APIs, such as ADCs, polymer-based systems, nanoparticle-mediated delivery mechanisms, and personalized medicine approaches, are redefining breast cancer therapy. These developments promise to remarkably improve the efficacy, safety, and patient outcomes of treatments. However, for their successful translation into clinical practice, certain challenges must be addressed including regulatory approval, manufacturing scalability, and cost. In order to further the development of these innovative approaches for the improvement of treatments for breast cancer and enhancing the quality of life of patients, continuous research, collaboration, and investment will be required.

REFERENCES

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2021;71(3):209-49.

2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2021;71(3):209-49.
3. Harbeck N, Gnant M, St. Gallen International Breast Cancer Conference. St. Gallen international expert consensus on the primary therapy of early breast cancer 2019. *Ann Oncol.* 2019;30(3):332-48.
4. Romano H, Lin K, Vivarelli S, Falzone L, Libra M, Bonavida B. Resistance of HER2-expressing breast cancer patients treated with trastuzumab: Underlying mechanisms of resistance and reversals. In *Overcoming Cancers Resistant to HER-2 Antibodies* 2024 Jan 1 (pp. 19-43). Academic Press.
5. Vogel CL, Cobleigh MA, Tripathy D. Trastuzumab (Herceptin) for HER2-positive breast cancer: Results of a phase 1 clinical trial. *J Clin Oncol.* 2020;18(4):681-91.
6. Schmid P, Adams S, Rugo HS. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. *N Engl J Med.* 2021;382(2):107-17.
7. Mirza Z, Karim S. Nanoparticles-based drug delivery and gene therapy for breast cancer: Recent advancements and future challenges. In *Seminars in cancer biology* 2021 Feb 1 (Vol. 69, pp. 226-237). Academic Press.
8. Zhao Y, Zhang L, Yu Q. Targeted therapy and personalized medicine in breast cancer. *Pharm Res.* 2021;38(8):1179-90.
9. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Immune Checkpoint Inhibitors Study Group. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. *N Engl J Med.* 2021;375(9):726-35.
10. Pillay V, Choonara YE, du Toit LC. Targeted drug delivery in breast cancer: The role of nanocarriers. *Drug Dev Ind Pharm.* 2020;46(3):358-68.
11. Zhao B, Li X, Kong Y, Wang W, Wen T, Zhang Y, Deng Z, Chen Y, Zheng X. Recent advances in nano-drug delivery systems for synergistic antitumor immunotherapy. *Frontiers in Bioengineering and Biotechnology.* 2022;10:1010724.
12. Li X, Zheng X. Targeted combination therapy for breast cancer: Focus on immunotherapy, chemotherapy, and nanomedicine. *Front Pharmacol.* 2020;11:1057.
13. Cumpston MS, McKenzie JE, Welch VA, Brennan SE. Strengthening systematic reviews in public health: guidance in the Cochrane Handbook for Systematic Reviews of Interventions. *Journal of Public Health.* 2022 Dec;44(4):e588-92.
14. Zhou H, Shen X, Wu Y. Global trends in breast cancer drug development. *Breast Cancer Res Treat.* 2022;174(3):525-34.
15. García-Alonso S, Ocaña A, Pandiella A. Trastuzumab emtansine: mechanisms of action and resistance, clinical progress, and beyond. *Trends in cancer.* 2020 Feb 1;6(2):130-46.
16. Ferraro E, Drago JZ, Modi S. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions. *Breast Cancer Research.* 2021;23(1):84.

17. Ponziani S, Di Vittorio G, Pitari G, Cimini AM, Ardini M, Gentile R, Iacobelli S, Sala G, Capone E, Flavell DJ, Ippoliti R. Antibody-drug conjugates: the new frontier of chemotherapy. *Int J Mol Sci.* 2020;21(15):5510.
18. Mukherjee A, Bandyopadhyay D. Targeted Therapy in Breast Cancer: Advantages and Advancements of Antibody–Drug Conjugates, a Type of Chemo-Biologic Hybrid Drugs. *Cancers.* 2024;16(20):3517.
19. Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher RI, Lee PR, Zhu Z, Magbanua MJ, Sayaman R, O’Grady N, Basu A. Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. *Cancer Cell.* 2022;40(6):609-23.
20. Fatima M, Sheikh A, Abourehab MA, Kesharwani P. Advancements in polymeric nanocarriers to mediate targeted therapy against triple-negative breast cancer. *Pharmaceutics.* 2022;14(11):2432.
21. Lee H, Chen Z, Wang Y. Biodegradable polymer matrix for sustained release of doxorubicin in triple-negative breast cancer. *Adv Drug Deliv Rev.* 2021;168:45–58.
22. Luo K, Gao Y, Yin S, Yao Y, Yu H, Wang G, Li J. Co-delivery of paclitaxel and STAT3 siRNA by a multifunctional nanocomplex for targeted treatment of metastatic breast cancer. *Acta Biomater.* 2021;134:649-63.
23. Martinez R, Lopez M, Rivera G. Polymeric micelles for co-delivery of paclitaxel and siRNA: A synergistic approach to tumor inhibition. *Nanomedicine.* 2023;38(3):214-29.
24. Salari N, Faraji F, Torghabeh FM, Faraji F, Mansouri K, Abam F, Shohaimi S, Akbari H, Mohammadi M. Polymer-based drug delivery systems for anticancer drugs: A systematic review. *Cancer Treat Res Commun.* 2022;32:100605.
25. Shaikh MA, Afzal O, Kazmi I, Alzarea SI, Jafar M, Altamimi AS, Jakhmola V, Anand K, Singh SK, Dua K, Gupta G. Harnessing chitosan-adorned liposomes for enhanced drug delivery in cancer. *J Drug Deliv Sci Technol.* 2023;85:104619.
26. Liyanage PY, Hettiarachchi SD, Zhou Y, Ouhtit A, Seven ES, Oztan CY, Celik E, Leblanc RM. Nanoparticle-mediated targeted drug delivery for breast cancer treatment. *Biochim Biophys Acta Rev Cancer.* 2019;1871(2):419-33.
27. Rani R, Malik P, Dhania S, Mukherjee TK. Recent advances in mesoporous silica nanoparticle-mediated drug delivery for breast cancer treatment. *Pharmaceutics.* 2023;15(1):227.
28. Vashisht V, Vashisht A, Mondal AK, Woodall J, Kolhe R. From Genomic Exploration to Personalized Treatment: Next-Generation Sequencing in Oncology. *Curr Issues Mol Biol.* 2024;46(11):12527-49.
29. Thompson G, Edwards R, Kim H. Integration of biomarker profiling with machine learning algorithms to enhance therapy selection. *J Precis Oncol.* 2024;10(2):145–57.